Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO: Aliskiren for CV Event Prevention in Elderly
NCT01259297Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of aliskiren in cardiovascular disease (CVD), hypertension (HTN), sponsored by Novartis. Started Jan 2011; status: terminated.
02
Drugs
aliskiren
03
Conditions
cardiovascular disease (CVD)hypertension (HTN)
Beyond the preview
Go deeper on NCT01259297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01259297.